S.C. will receive more than $360 million over the next 18 years

Press release: imph releases guide for local policymakers in use of opioid settlement funds 1

Left to right: Hunter Sox, IMPH; Jared Libet, Office of the South Carolina Attorney General; Senator Katrina Frye Shealy; Attorney General Alan Wilson; Governor Henry McMaster; Representative Patricia Moore Henegan; Richard Wilkerson, IMPH Board; Sara Goldsby, DAODAS

COLUMBIA, S.C. (June 22, 2022) — The South Carolina Institute of Medicine and Public Health (IMPH), in partnership with the South Carolina Department of Alcohol and Other Drug Abuse Services (DAODAS), hosted a press conference regarding the recent opioid settlement and released IMPH’s new report: South Carolina’s Guide to Approved Uses for Investing Opioid Settlement Funds. The report includes recommendations by a group of subject matter experts and is meant to serve as a resource for county and municipal policymakers on appropriate strategies that can be funded by South Carolina opioid settlement funds from this and future settlements.

On February 25, 2022, the National Prescription Opiate Litigation Plaintiffs’ Executive Committee (PEC) finalized settlements totaling $26 billion with the “Big Three” drug distributors – AmerisourceBergen, Cardinal Health and McKesson – and opioid manufacturer Johnson & Johnson. Fifty-two states and territories and thousands of local governments across the country signed on to the agreement.

In addition to the national agreements, South Carolina Attorney General Alan Wilson worked with the state’s counties and eligible municipalities to allocate more than $360 million coming to South Carolina over the next 18 years. Through an agreement reached by Wilson and the litigating counties, 92% of these funds will be used to directly address the opioid crisis.

As part of the South Carolina Opioid Settlement Allocation Agreement, the state has enacted legislation to allow settlement funds to be sent to approved counties and municipalities and created the South Carolina Opioid Recovery Fund Board to manage and disburse the settlement funds. The board will be comprised of nine members who will be appointed and representative of the four regions of the state.

IMPH’s report suggests that all funds in the South Carolina Opioid Recovery Fund should be used for one or more of the following approved opioid remediation uses:

  • Naloxone or other FDA-approved drug to reverse opioid overdoses.
  • Medications for Opioid Use Disorder (MOUD) distribution and other opioid-related treatment.
  • Treatment for pregnant and postpartum women.
  • Expanding treatment for Neonatal Abstinence Syndrome (NAS).
  • Expansion of warm hand-off programs and recovery services.
  • Treatment for incarcerated population.
  • Prevention programs.
  • Expanding syringe service programs.
  • Evidence-based data collection and research analyzing the effectiveness of the abatement strategies within the state.

These core strategies will support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder or Mental Health (SUD/MH) conditions through evidence-based or evidence-informed programs or strategies. For more information, read the full report here.

IMPH and DAODAS convened the following subject matter experts to develop this report:

  • Christina M. Andrews, PhD
    • Associate Professor, Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina
  • Kathleen T. Brady, MD, PhD
    • Distinguished University Professor; Director, South Carolina Clinical and Translational Research Institute, Medical University of South Carolina
  • Sara Goldsby, MSW, MPH
    • Agency Director, South Carolina Department of Alcohol and Other Drug Abuse Services
  • Alain H. Litwin, MD, MPH
    • Executive Director, Prisma Health Addiction Medicine Center
    • Vice Chair of Academics and Research, Department of Medicine, Prisma Health
    • Professor of Medicine, University of South Carolina School of Medicine – Greenville
    • Professor, Clemson University School of Health Research
  • Edward Simmer, MD, MPH, DFAPA
    • Agency Director, South Carolina Department of Health and Environmental Control

For more information on the settlement, the contributors and more, access the full report.

About IMPH

The South Carolina Institute of Medicine & Public Health (IMPH) is a nonpartisan, nonprofit organization working to collectively inform policy to improve health and health care in South Carolina. In conducting its work, IMPH takes a comprehensive approach to advancing health issues through data analysis and translation and collaborative engagement. IMPH seeks to achieve its mission by convening a diverse group of stakeholders around health issues important to South Carolina. Learn more at imph.org.